The firm’s product pipeline includes OTIVIDEX Meniere’s disease, OTIPRIO acute otitis media with tubes , OTO-313 tinnitus, OTO-413 hidden hearing Loss, OTO-510 prevent CIHL, OTO-6XX severe hearing loss. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. As of Dec.1, 2022, Otonomy’s market capitalization was $10.23M. The total selling price of a publicly listed company’s outstanding shares is known as market cap . The market capitalization of Otonomy is computed by dividing the $0.18 share price of OTIC by the 57,153,490 shares that are currently in circulation.
Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. OTIC’s profits for 2022 are expected to be, on average, -$41,722,048 by 3 Wall Street analysts, with the lowest estimate being -$45,722,792 and the highest estimate being -$37,149,769. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market.
Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus.
Otonomy (OTIC)
The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States.
Otonomy plans to liquidate, lays off all employees; stock drops 20% – Seeking Alpha
Otonomy plans to liquidate, lays off all employees; stock drops 20%.
Posted: Tue, 20 Dec 2022 08:00:00 GMT [source]
The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability – yield is subject to change. Past performance is not indicative of future performance. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates.
View All
What analysts recommend for OTIC stock, on a scale from 1 to 5. Since the price of Otonomy stock has been trending downward, we assume that similar segmentations were not very well-liked during the time frame. Our prediction method projects the stock’s future price to be $0 (-100%) after a year. Below are the latest news stories about OTONOMY INC that investors may wish to consider to help them evaluate OTIC as an investment opportunity. There are currently no analyst ratings available for Otonomy. Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with…
North American Morning Briefing: Stock Futures -3- – Morningstar
North American Morning Briefing: Stock Futures -3-.
Posted: Mon, 03 Apr 2023 07:00:00 GMT [source]
With the lowest OTIC revenue prognosis at $21,718,326, and the greatest OTIC stock forecast at $21,718,326 on average, 1 Wall Street analysts expect OTIC to generate $21,718,326 in sales in 2023. On the balance sheet of OTIC, short-term assets outnumber long-term liabilities. On the balance sheet of OTIC, short-term assets outnumber short-term liabilities. In order to develop and market gene therapy for congenital hearing loss, the company has license agreements with the University of California, DURECT Corporation, and Applied Genetic Technologies Corporation.
How Much Money Did OTIC Make The Last Quarter?
The https://1investing.in/ was founded in 2008 and is based in San Diego, California. There is currently no analyst price target forecast available for Otonomy. OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints Company to discontinue development of OTO-313 and implement… There may be delays, omissions, or inaccuracies in the Information.
- JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries.
- 2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Otonomy in the last twelve months.
- Otonomy Inc 52 week low is $0.0075 as of April 28, 2023.
Based on these findings, brent wti spread stopped working on OTO-313 and took additional steps to increase its cash runway. Investing.com – U.S. equities were lower at the close on Thursday, as losses in the Industrials, Technology and Basic Materials sectors propelled shares lower. Real-time analyst ratings, insider transactions, earnings data, and more. U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC.
Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding.
In contrast, Otonomy’s stock price is 19% more unpredictable than the S&P 500. When compared by MarketBeat users, Otonomy received 46 more exceed votes than Rockwell Medical. Similarly, 63.08% of people voted for Otonomy to outperform, whereas just 59.27% of users chose Rockwell Medical.
Furthermore, Otonomy has shown in preclinical research that the restoration of auditory function is connected to the repair of synaptic connections. Initial clinical investigations have shown that OTO-413 is well tolerated and enhances hearing performance in a number of clinically recognized speech-in-noise hearing tests after a single intratympanic injection. Otonomy Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear.
- According to the consensus Otonomy stock projection, the price of OTIC stock might rise by 1,715.64% from its current price of $0.18.
- 52 week high is the highest price of a stock in the past 52 weeks, or one year.
- Real-time analyst ratings, insider transactions, earnings data, and more.
These does include a labor reduction of about 55%, the majority of which was accomplished by the end of August. EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. The technique has proven to be very useful for finding positive surprises.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
See Jiko U.S. Treasuries Risk Disclosures for further details. On August 13, 2014, Otonomy stock went public at a price of $17.15. Your return over the last eight years would be -98.96%, for an annualized return of -43.46%, if you had purchased Otonomy stock at $17.15. Compared to Otonomy, Rockwell Medical has larger revenue and earnings.
There are 12 OTIC stock forecast made for every month of 2026. Two Wall Street experts have predicted prices for OTIC for the next year; the average price target for OTIC is $3.25, with the greatest price target being $6.00 and the lowest being $0.50. A beta of 1.02 indicates that Rockwell Medical’s stock price is 2% more unpredictable than the S&P 500.
During the event, we even reveal An-E’s predictions of the stock prices of TSLA, NVDA, and AAPL for FREE. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. Discuss news and analysts’ price predictions with the investor community. In a Phase 2 clinical trial in people with tinnitus, Otonomy reported that OTO-313 showed no clinically marked improvement versus placebo for both the primary and secondary endpoints.
Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. One share of OTIC stock can currently be purchased for approximately $0.01. When you see Otonomy stock appear in the results, tap it to open up the purchase screen. OTIC is anticipated to earn -$19,432,187 in 2024, with the lowest earnings estimate coming in at -$24,004,466 and the highest at -$14,859,907. OTIC’s EPS is expected to be -$0.58 on average for 2023, the with lowest estimate coming in at -$0.85 and the highest at -$0.39.
By October 13, 2023, on average, Wall Street analysts expect Otonomy’s share price to reach $3.25. According to the consensus Otonomy stock projection, the price of OTIC stock might rise by 1,715.64% from its current price of $0.18. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share .
Where Does Otonomy Inc (OTIC) Stock Fall in the Biotechnology Field After It Is Up 137.50% This Week? – InvestorsObserver
Where Does Otonomy Inc (OTIC) Stock Fall in the Biotechnology Field After It Is Up 137.50% This Week?.
Posted: Tue, 29 Nov 2022 08:00:00 GMT [source]
This indicates that you shouldn’t add this stock to your portfolio because trading in market downturns is always more difficult, especially for novice traders. OTIC stock has a valuation score of 43, which is higher than the industry average for the biotechnology sector. Currently, OTIC stock is able to pass three of seven requirements for due diligence.
“Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of (“Regulation A”). These investments are speculative, involve substantial risks , and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. Engages in the development of therapeutics for neurotology.
The consensus among Wall Street equities research analysts is that investors should “hold” OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares. Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC.
JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy. JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity).
The Indian finance minister suggested against using cryptocurrency.The law enforcement organization blocked the assets of two crypto exchanges.At a BJP Economic Cell event on Saturday,… 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Otonomy Inc 52 week low is $0.0075 as of April 28, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
Recent Comments